Bioinformatics analysis and expression profile analysis of prognostic related genes in the tumor microenvironment of endometrial carcinoma

  • DING Caiyun ,
  • MA Qiang ,
  • DING Jin ,
  • WANG Haihua ,
  • LI Jin ,
  • SUN Li
Expand
  • 1. School of Basic Medical Sciences, Wannan Medical College, Wuhu 241002,China;
    2. Department of Ultrasound, Yijishan Hospital of Wannan Medical College;
    3. Department of Gynaecology and Obstetrics, Yijishan Hospital of Wannan Medical College

Received date: 2023-09-04

  Online published: 2024-08-07

Abstract

Objective:To explore the key prognostic genes in the tumor microenvironment of endometrial carcinoma by bioinformatics analysis and PCR expression verification. Methods: The gene expression data of 552 patients with endometrial carcinoma were downloaded from TCGA database, and the immune score and interstitial score were performed by R software ESTIMATE algorithm to screen the differentially expressed genes. A variety of algorithms were used to further explore the prognosis of differential genes and related pathways. PCR assay was used to analyze the expression correlation of differential genes in clinical tissues and cell lines. Results: Cox regression analysis and KM survival analysis indicated that CCR4 was a potential prognostic gene. GSEA and KEGG results showed that CCR4 was significantly enriched in the immune response-activation cell surface receptor signaling pathway. The results of RT-qPCR showed that the expression of CCR4 in tumor group was significantly higher than that in non-tumor group at cell level and tissue level. Conclusion: Immunoinfiltration exists in the tumor microenvironment of endometrial carcinoma, and CCR4 is expected to be a new diagnostic marker for endometrial carcinoma.

Cite this article

DING Caiyun , MA Qiang , DING Jin , WANG Haihua , LI Jin , SUN Li . Bioinformatics analysis and expression profile analysis of prognostic related genes in the tumor microenvironment of endometrial carcinoma[J]. Journal of Baotou Medical College, 2024 , 40(7) : 1 -8 . DOI: 10.16833/j.cnki.jbmc.2024.07.001

References

[1] Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of figo grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists[J]. Int J Gynecol Pathol, 2019, 38 Suppl 1(Iss 1 Suppl 1): S64-S74.
[2] Travaglino A, Arciuolo D, Santoro A, et al. Corded and hyalinized endometrioid carcinoma: summary of clinical, histological, immunohistochemical and molecular data[J]. Pathol Res Pract, 2023, 247: 154515.
[3] Walsh CS, Hacker KE, Secord AA, et al. Molecular testing for endometrial cancer: an sgo clinical practice statement[J]. Gynecol Oncol, 2023, 168: 48-55.
[4] Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, et al. Facts and hopes in immunotherapy of endometrial cancer[J]. Clin Cancer Res, 2022, 28(22): 4849-4860.
[5] Rousset-Rouviere S, Rochigneux P, Chrétien AS, et al. Endometrial carcinoma: immune microenvironment and emerging treatments in immuno-oncology[J]. Biomedicines, 2021, 9(6): 632.
[6] Ketcham JM, Marshall LA, Talay O. CCR4 antagonists inhibit T(reg) trafficking into the tumor microenvironment[J]. ACS Med Chem Lett, 2018, 9(10): 953-955.
[7] Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy[J]. Cancers (Basel), 2021, 13(21): 5542.
[8] Zhang Y, Chen K, Li L, et al. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma[J]. Ann Transl Med, 2021, 9(18): 1443.
[9] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[10] Lu KH, Broaddus RR. Endometrial cancer[J]. N Engl J Med, 2020, 383(21): 2053-2064.
[11] Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(9): 860-877.
[12] Cai Y, Wang B, Xu W, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine[J]. Curr Med Chem, 2021, 28(42): 8755-8781.
[13] Harkenrider MM, Abu-Rustum N, Albuquerque K, et al. Radiation therapy for endometrial cancer: an American society for radiation oncology clinical practice guideline[J]. Pract Radiat Oncol, 2023, 13(1): 41-65.
[14] Passarello K, Kurian S, Villanueva V. Endometrial cancer: an overview of pathophysiology, management, and care[J]. Semin Oncol Nurs, 2019, 35(2): 157-165.
[15] Vural F, Coşkun ADE, Çιtak G, et al. The comparison of inflammatory markers in geriatric and nongeriatric endometrial cancers[J]. Cancer Biomark, 2022, 34(4): 583-590.
[16] Xu M, Zhang T, Xia R, et al. Targeting the tumor stroma for cancer therapy[J]. Mol Cancer, 2022, 21(1): 208.
[17] Li BL, Wan XP. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer[J]. J Cell Mol Med, 2020, 24(14): 7767-7777.
[18] Antomarchi J, Ambrosetti D, Cohen C, et al. Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma[J]. Cancer Microenviron, 2019, 12(2-3): 169-179.
[19] He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Ther, 2021, 6(1): 425.
[20] Diéguez-Martínez N, Espinosa-Gil S, Yoldi G, et al. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival[J]. Cell Mol Life Sci, 2022, 79(10): 524.
[21] Li J, Ruffell B. Cytokines drive prostate cancer lineage plasticity[J]. Immunity, 2022, 55(10): 1761-1763.
[22] Zhang X, Luo Y, Cen Y, et al. MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1[J]. Cell Death Dis, 2022, 13(11): 923.
[23] Bogacka J, Pawlik K, Ciapała K, et al. CC chemokine receptor 4 (CCR4) as a possible new target for therapy[J]. Int J Mol Sci, 2022, 23(24): 15638.
[24] Ono S, Suzuki S, Kondo Y, et al. Trametinib improves treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma[J]. Sci Rep, 2022, 12(1): 21678.
[25] Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy[J]. Mol Cell, 2020, 78(6): 1019-1033.
[26] Zilio S, Bicciato S, Weed D, et al. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor[J]. J Immunother Cancer, 2022, 10(1): e003131.
[27] Shen W, Zhang X, Tang J, et al. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis[J]. Theranostics, 2021, 11(5): 2297-2317.
[28] Meng J, Wang L, Hou J, et al. CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop[J]. Cancer Sci, 2021, 112(8): 3099-3110.
[29] Kanagawa N, Niwa M, Hatanaka Y, et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma[J]. Int J Cancer, 2007, 121(9): 2013-2022.
Outlines

/